The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study

被引：0
|
作者：
Wen-Chien Cheng
Chi-Chien Lin
Wei-Chih Liao
Yu-Chao Lin
Chia-Hung Chen
Hung-Jen Chen
Chih-Yen Tu
Te-Chun Hsia
机构：
[1] China Medical University Hospital,Division of Pulmonary and Critical Care, Department of Internal Medicine
[2] China Medical University,School of Medicine, College of Medicine
[3] National Chung Hsing University,Department of Life Science
[4] National Chung Hsing University,PhD Program in Translational Medicine
[5] National Chung Hsing University,Rong Hsing Research Center for Translational Medicine
[6] National Chung-Hsing University,Institute of Biomedical Science, the iEGG and Animal Biotechnology Center, Advanced Plant and Food Crop Biotechnology Center
[7] Kaohsiung Medical University,Department of Pharmacology, College of Medicine
[8] Taichung Veterans General Hospital,Department of Medical Research
来源：
BMC Cancer | / 24卷
关键词：
Non-small cell lung cancer (NSCLC); Epidermal growth factor receptor (EGFR); Dacomitinib; Afatinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Real-world experience with afatinib as first-line treatment in advanced non-small cell lung cancer in a university hospital
    Jang, Taewon
    Kim, Jaehoon
    CANCER RESEARCH, 2019, 79 (13)
  • [22] Real World Study of Afatinib in First-Line or Re-Challenge Setting for Patients with EGFR Mutant Non-Small Cell Lung Cancer
    Tanaka, H.
    Taima, K.
    Itoga, M.
    Ishioka, Y.
    Baba, K.
    Shiratori, T.
    Tanaka, Y.
    Nakagawa, H.
    Morimoto, T.
    Hasegawa, Y.
    Yasugahira, H.
    Okudera, K.
    Takanashi, S.
    Tasaka, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S984 - S984
  • [23] Real world study of afatinib in first-line or re-challenge setting for patients with EGFR mutant non-small cell lung cancer
    Tanaka, Hisashi
    Taima, Kageaki
    Itoga, Masamichi
    Ishioka, Yoshiko
    Baba, Keisuke
    Shiratori, Toshihiro
    Tanaka, Yoshihito
    Nakagawa, Hideyuki
    Tsuchiya, Junichiro
    Hasegawa, Yukihiro
    Sakamoto, Hiroaki
    Yasugahira, Hideo
    Okudera, Koichi
    Takanashi, Shingo
    Tasaka, Sadatomo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] First-Line Afatinib Dose Initiation and Adjustment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer
    Liam, C.
    Ho, G.
    Chai, C.
    Alip, A. Bt
    Pang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S981 - S982
  • [25] A Real World Cohort Study of First Line Afatinib in Patients with EGFR mutant Advanced Non Small Cell Lung Cancer in Vietnam
    Pham, P. C.
    Nguyen, H. T. T.
    Do, T. A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S668 - S669
  • [26] A large real-world study on the effectiveness of the combined inhibition of EGFR and MET in EGFR-mutant advanced non-small cell lung cancer (NSCLC).
    Li, Liu
    Qu, Jingjing
    Heng, Jianfu
    Zhou, Chunhua
    Xiong, Yi
    Yang, Haiyan
    Jiang, Wenjuan
    Zeng, Liang
    Zhu, Songlin
    Zhang, Yongchang
    Tan, Jiarong
    Hou, Ting
    Lizaso, Analyn
    Chen, Zhiqiu
    Hu, Chengping
    Deng, Pengbo
    Yang, Nong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] Real-World Effectiveness of EGFR TKI First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in US
    Gautam, S.
    Herms, L.
    Bartolome, L.
    Pastel, M.
    Wilner, K.
    Fisher, M.
    Ivanova, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S618 - S619
  • [28] The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan (vol 17, pg 295, 2022)
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Tseng, Jeng-Sen
    Yang, Tsung-Ying
    Chen, Kun-Chieh
    Su, Kang-Yi
    Yu, Sung-Liang
    Chen, Jeremy J. W.
    Chang, Gee-Chen
    TARGETED ONCOLOGY, 2023, 18 (01) : 179 - 180
  • [29] Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
    Lee, Sung Yong
    Choi, Chang-Min
    Chang, Yoon Soo
    Lee, Kye Young
    Kim, Seung Joon
    Yang, Sei Hoon
    Ryu, Jeong Seon
    Lee, Jeong Eun
    Lee, Shin Yup
    Park, Ji Young
    Kim, Young-Chul
    Oh, In-Jae
    Jung, Chi Young
    Lee, Sang Hoon
    Yoon, Seong Hoon
    Choi, Juwhan
    Jang, Tae Won
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (12) : 4353 - +
  • [30] Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer
    Nishio, Makoto
    Kato, Terufumi
    Niho, Seiji
    Yamamoto, Noboru
    Takahashi, Toshiaki
    Nogami, Naoyuki
    Kaneda, Hiroyasu
    Fujita, Yuka
    Wilner, Keith
    Yoshida, Mizuki
    Isozaki, Mitsuhiro
    Wada, Shinsuke
    Tsuji, Fumito
    Nakagawa, Kazuhiko
    CANCER SCIENCE, 2020, 111 (05) : 1724 - 1738
12345